Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug PT0511 targets Hard-to-Treat KRAS cancers in early trial

NCT ID NCT07300150

Recruiting now Disease control Sponsor: PAQ Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 participants with colorectal, pancreatic, lung, or other solid tumors will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PT0511 (intravenous infusion) and cetuximab (intravenous infusion)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers with KRAS mutations, such as colorectal, pancreatic, or lung cancer.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if PT0511 will work. Side effects and lack of efficacy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER NON-SMALL CELL LUNG CANCER PANCREATIC CANCER SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Dana-Farber/Massachusetts General Hospital, Inc

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • New Experimental Therapeutics of San Antonio LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

  • START - South Texas Accelerated Research Therapeutics, LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    RECRUITING

    Seoul, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.